Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
Kohara T, Nakayama K, Watanabe K, Kusaka SI, Sakai D, Tanaka H, Fukunaga K, Sunada S, Nabeno M, Saito KI, Eguchi JI, Mori A, Tanaka S, Bessho T, Takiguchi-Hayashi K, Horikawa T. Kohara T, et al. Among authors: nabeno m. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3733-3738. doi: 10.1016/j.bmcl.2017.06.077. Epub 2017 Jul 5. Bioorg Med Chem Lett. 2017. PMID: 28712706
Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease.
Fukunaga K, Sakai D, Watanabe K, Nakayama K, Kohara T, Tanaka H, Sunada S, Nabeno M, Okamoto M, Saito K, Eguchi J, Mori A, Tanaka S, Inazawa K, Horikawa T. Fukunaga K, et al. Among authors: nabeno m. Bioorg Med Chem Lett. 2015 Mar 1;25(5):1086-91. doi: 10.1016/j.bmcl.2015.01.005. Epub 2015 Jan 13. Bioorg Med Chem Lett. 2015. PMID: 25655721
Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
Usui Y, Uehara F, Hiki S, Watanabe K, Tanaka H, Shouda A, Yokoshima S, Aritomo K, Adachi T, Fukunaga K, Sunada S, Nabeno M, Saito KI, Eguchi JI, Yamagami K, Asano S, Tanaka S, Yuki S, Yoshii N, Fujimura M, Horikawa T. Usui Y, et al. Among authors: nabeno m. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3726-3732. doi: 10.1016/j.bmcl.2017.06.078. Epub 2017 Jul 5. Bioorg Med Chem Lett. 2017. PMID: 28712708
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, Ishige T, Shima K, Nabeno M, Abe Y, Anabuki J, Soejima A, Yoshida K, Takashina Y, Ishii S, Kiuchi S, Fukuda S, Tsutsumiuchi R, Kosaka K, Murozono T, Nakamaru Y, Utsumi H, Masutomi N, Kishida H, Miyaguchi I, Hayashi Y. Yoshida T, et al. Among authors: nabeno m. Bioorg Med Chem. 2012 Oct 1;20(19):5705-19. doi: 10.1016/j.bmc.2012.08.012. Epub 2012 Aug 17. Bioorg Med Chem. 2012. PMID: 22959556